Reddit Posts
PIPE to Float Chart (10/30/2021) - HUMA EFFECT 10/25, BKSY S-1 10/25, LILM EFFECT 10/27, ACHR EFFECT 10/26, SHPW EFFECT 10/27, VLD EFFECT 10/28, ARBE S-1 10/29, MIR S-1 10/27
PIPE to Float Chart (10/23/2021) - IONQ S-1/A 10/22, VLD S-1 10/21, ML EFFECT 10/22, ACHR S-1/A 10/22, LFG EFFECT 10/21, TMC EFFECT 10/21, HUMA S-1/A 10/21
Mentions
LISTEN TO THIS: HUMA is one of the few companies green in pre-market. +3.3%. WHY?????? The Company is engaged in [...] to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. U FUCKING KNOW EHAT THIS MEANS MOTHERFUCKERS.
$HUMA coming back like crazy
$HUMA is dropping crazy
HUMA said in their last earnings call that their cash runway would get them through most of 2026 🤣 what a crazy bunch huh
Just have to say HUMA is absolute trash. Awese tech, dilution machine
$HUMA They make artificial, off-the-shelf (out of a box) blood vessels that are not detected by the immune system. They are already *FDA approved* for a very niche indication (limb salvage from trauma). If the rest of their pipeline (dialysis, CABG, peripheral artery disease) shows similar data, this will go gang busters. Or they’ll go bankrupt first.
HUMA has $2 strike options for January '27 for for .35 right now!
Not sure exactly as I made a ~600 dollar option gamble on snap earnings and LOST ALL THAT but my portfolio seems to only be down around that much. Got lucky and bought a bunch of Moderna all at once at 33.05 so that has definitely propped up EVERYTHING else. Next best gain after that is HUMA but I only have a hundred in them AND I once again got lucky with timing and am somehow up on that shit stock.
Exiting HUMA. There's just no use for it now dead people are walking round with no legs.
Buying more HUMA and PLTR
Is this like HUMA where they take your money and dump their shares over and over?
Thanks for the reminder to check on my HUMA bags
PACB, CYRX, and HUMA. I strongly believe the future will be more fundamentally genetic (medicine, plastics and textiles from genetically modified organisms, food chain, etc). PACB - dense, full context reads of genetic material at a cheap price point. This has quality control and pipeline integrity all over it. CYRX - anything biological that is transported needs constant temperatures. Big, small, food, custom medicine (read genes - discover preventable - deliver custom tailored meds), applicable everywhere and they are finding more efficient, non liquid nitrogen based methods. HUMA - if it makes it through this year or two, this is the standard of care for vascular tissue (plus scaffolding for all kinds of delivery approaches) with a patent until late 2030s.
HUMA looks like it will move today
$HUMA - With new DoD funding designed to procure biologic vascular repair technologies, HUMA is poised to bid. Technology. SYMVESS™ (acellular tissue engineered vessel-tyod) in-class, bioengineered human tissue developed by Humacyte for repairing, replacing, or bypassing damaged arteries. Approved by the FDA in December 2024 for urgent vascular trauma, it is designed as an off-the-shelf, universal implant to treat limb-threatening injuries when autologous veins are unavailable, showing high patency and low infection rates. Volume is low and needs to pick up for this to ride
HUMA DOD is procuring bioengineer blood vessels. AVGO just warming up for run before earning.
$HUMA - With new DoD funding designed to procure biologic vascular repair technologies, HUMA is poised to bid. Technology. SYMVESS™ (acellular tissue engineered vessel-tyod) in-class, bioengineered human tissue developed by Humacyte for repairing, replacing, or bypassing damaged arteries. Approved by the FDA in December 2024 for urgent vascular trauma, it is designed as an off-the-shelf, universal implant to treat limb-threatening injuries when autologous veins are unavailable, showing high patency and low infection rates.
Also HUMA has been developing a technology that has been approved by the FDA, now with new interest through funding it looks very positive. Technology. SYMVESS™ (acellular tissue engineered vessel-tyod) in-class, bioengineered human tissue developed by Humacyte for repairing, replacing, or bypassing damaged arteries. Approved by the FDA in December 2024 for urgent vascular trauma, it is designed as an off-the-shelf, universal implant to treat limb-threatening injuries when autologous veins are unavailable, showing high patency and low infection rates.
$HUMA - D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target AH play
HUMA, ive been watching, worth a look
Check HUMA, worth a look
HUMA - Got big DoD contract, within a range but AH can be something good to the plus side
HUMA news not bad i think? This stock is so oversold. Might swing back to 2
[https://www.stocktitan.net/news/HUMA/humacyte-announces-new-u-s-department-of-defense-funding-for-cfs75tjwvj3x.html](https://www.stocktitan.net/news/HUMA/humacyte-announces-new-u-s-department-of-defense-funding-for-cfs75tjwvj3x.html)
Another problem for me and biotechs is everytime i look into them i feel like there is 20 billion diseases i never knew about that dont have reliable treatments. Turns me into a hypochondriac I took my very modest (small) biotech swing on HUMA a few weeks back. Mentally prepared myself for it to go to 0.
Fuck HUMA I bought them at like $5 and their shit isn't ever gonna go.
HUMA has been quite frustrating. ARSMF has been recently frustrating but the U.S. government saw enough in their potential to develop a mine to commit about $150M as I recall (dependent on the fluorospar they mine)
I’m not in IBRX but in SLS and DRTS. Hit my threshold for speculative stocks investments. Waiting on one of these including HUMA and ARSMF to moon, hopefully.
CSU (Constellation Software) is the safest bet from your list - proven acquirer, actual earnings, just had a pullback. Not a pennystock tho, its like $3k/share in CAD. SMR is interesting with the nuclear energy narrative but its pre-revenue and priced for perfection. If nuclear sentiment shifts you’re bagholding. HIVE and WWR are crypto/commodities proxies - if you’re bullish on those just buy BTC or lithium directly instead of adding company risk on top. ONDS and HUMA - don’t know enough to comment, which usually means they’re too speculative for me. Honestly with 10k after +123% gains, taking some off the table and putting it into something boring like QQQM or VOO isnt the worst idea. You already won, dont need to gamble it all again.
Here's a report I made for HUMA with my deep research tool if you want a quick start: [HUMA report](https://app.deepvalue.tech/report-share/TpiikawIdMBr)
I had a bunch of HUMA I bought at 5. Fuck this stock.
Ibrx and sls are cheap so I guess it can't hurt I might buy into them but once you notice how many bio companies are out there and how cheap the stocks are it can make things confusing. I'm looking at HUMA but ehhh could be a money burn.
Great take on $HUMA! Don't forget, their partnerships with military and trauma centers could really amplify demand for Symvess. I’ve been tracking the price action here: https://aimytrade.io/ticker/HUMA?utm_source=reddit&utm_medium=comment&utm_campaign=pennystocks. Let’s see how this unfolds!
DGXX, HUMA, MDAI. Major catalysts inbound for all three. Already deep in the money on DGXX.
Just opinions, definitely do your own DD/research, but these are my plays and working theses: $AMPX - my thesis for AMPX rests on a demonstrable divergence between its forensic financial reality and its distressed market valuation as of January 2026. While the market continues to price the equity as a speculative R&D venture, the company’s Q3 2025 financials confirm a commercial inflection point characterized by 173% year-over-year revenue growth and, crucially, a shift to positive 15% gross margins—a rarity for early-stage hardware firms. This margin profile validates the unit economics of their silicon anode technology, proving that industrial customers in the aviation and defense sectors are willing to pay a premium for superior energy density. Furthermore, the implementation of a capital-efficient "Fab-Light" manufacturing strategy allows for rapid backlog conversion without the immediate need for dilutive financing, creating a favorable risk-reward profile supported by a $53 million backlog and a geopolitical tailwind favoring non-Chinese battery supply chains. $DGXX - classic deep value opportunity driven by a stark disconnect between its current market capitalization and the intrinsic value of its tangible assets. The stock is currently trading at a valuation that barely exceeds its \~$100 million liquidity position, implying that the market is assigning a near-zero enterprise value to its operating business and 196.7 MW of secured power infrastructure. This creates a significant margin of safety for investors, as the debt-free balance sheet mitigates bankruptcy risk while the company executes a capital-intensive pivot from low-multiple cryptocurrency mining to high-margin AI colocation and GPU-as-a-Service. If management successfully deploys its ARMS 200 units and monetizes the recently announced 1.3 GW capacity pipeline, the stock could undergo a violent multiple expansion, re-rating from a distressed commodity play to an AI infrastructure asset. $HUMA - dislocation between price and intrinsic value, trading at a market capitalization of roughly $182 million that fails to reflect the sunk cost and strategic utility of its FDA-approved bio-manufacturing platform. The current valuation appears to price the asset solely on the immediate, friction-heavy revenue ramp of its trauma indication ignoring the "strategic put" offered by its Department of Defense ECAT listing and the substantial option value embedded in its Phase 3-validated dialysis pipeline. With a strengthened balance sheet extending the cash runway into late 2026, the market is discounting a commercial-stage biologic to near-liquidation levels, creating a highly asymmetric risk/reward profile for people (like me) willing to look past the temporary lag of hospital procurement cycles to the broader adoption curve and pipeline expansion. $MDAI - event-driven value opportunity where the market has inefficiently priced the company's transition from clinical development to commercialization. The recent contraction in equity value, driven largely by a headline decline in R&D revenue, fundamentally misinterprets the completion of pivotal government-funded trials as operational weakness rather than a necessary precursor to the FDA decision expected in the first half of 2026. With the DeepView System demonstrating statistically significant superiority over human clinical judgment in burn assessment and a liquidity runway secured through non-dilutive BARDA contracts and debt facilities, the current valuation offers an risk-reward profile that fails to account for the company's defensive IP moat and the high probability of regulatory clearance. $POET - presents a compelling long opportunity driven by its successful pivot from a capital-constrained R&D firm to a commercial manufacturer with a fortified balance sheet. The company recently secured approximately $250 million in equity financing, effectively eliminating near-term insolvency risk and providing the liquidity necessary to scale production of its Optical Interposer platform without the overhang of immediate dilution. This capital injection aligns with a critical point in the semiconductor cycle, where data center infrastructure is hitting physical limitations with copper interconnects, necessitating a shift to optical solutions 1.6T data speeds. With validated partnerships like the 1.6T optical engine collaboration with semtech and indirect exposure to Amazon’s hardware roadmap through the Marvell/Celestial AI acquisition, POET has product-market fit in a high-growth vertical. Consequently, the stock currently reflects a valuation dislocation, trading on irrelevant trailing financials rather than its emerging earnings power and strategic position within the AI hardware supply chain. I'm also long NVDA/GOOGL/IONQ.
Most of them, especially when I was new to trading. Too many speculative biopharma, and I wasn't really looking at things like p/e ratio - just assumed they'd moon. They need capital to do what they do, and they have products with good results that I believe in, but I should have stayed away. BMEA, TOVX, RVPH, INTS, SKYE, HUMA, FEMY, RVPH.
anyone know why HUMA all the analystist are saying $3-10 by end of year? A few different sites are saying that, anyone tracking the company or has some in their portfolio?
Every time I see a post like this people simply post all of the stocks that happened to go up 2-10x over the last six months. Basically everything has to go right this year for many of these stocks to keep running. If you want to speculate then I'd advise looking for some more asymmetric bets, stocks that may be unduly out of favour, not stocks that have already done so well. Full disclosure, I've been in RKLB and ASTS since they were ~$5 stocks, the risk/reward has changed completely since then, I'm trimming slightly, not buying. Some of my speculative positions for this year are HUMA, QS, FLNC, POET, SANA small market caps, likely mis-priced if they can achieve what they promise, they may well not achieve what they promise however haha.
Something $HUMA can definitely help with down the line
This was the most helpful. I bought POET, sold on loss but will buy back. Sold ONDS and RCAT at loss in Nov when I thought market was crashing… darn market manipulators. My problem was that I didn’t do DD. ASTS was the one I read everything about and so I held and it’s been great. I sold so many winners in Nov because I didn’t have conviction. Holding ACHR and Joby also. Might buy HUMA after reading this- 1000 shares would be so cheap right now
Impressive list. Let me verify against current prices and add context on your "next" picks: **Your Claimed Winners (Verified):** | Ticker | Your Entry | Current | Return | Verdict | |:-------|:-----------|:--------|:-------|:--------| | RKLB | $5 | $75.99 | **+1,420%** | Verified MONSTER | | ASTS | $10 | $83.47 | **+735%** | Verified MONSTER | | PLTR | $20 | $167.86 | **+739%** | Verified MONSTER | | PL | $6 | $20.41 | **+240%** | Verified | | LUNR | $4 | $17.88 | **+347%** | Verified | | BBAI | $3 | $5.84 | **+95%** | Verified | | NBIS | $55 | $89.95 | **+64%** | Verified | | ACHR | $4 | $8.13 | **+103%** | Verified | That's legitimate alpha. But here's the **challenge** on your forward picks: **POET Reality Check:** - Market Cap: **$640 million** (still small) - Q3 Revenue: **$0.3 million** - Q3 Loss: -$9.4 million - Op Margin: **-3,200%** This is genuine "early stage" risk. No revenue inflection yet. **HUMA Reality Check:** - Current Price: $0.975 (+1.5% from 52W low) - **80% below 52-week high** - Q3 Revenue: $0.75M, Loss: -$17.5M - Market Cap: $150M HUMA isn't "down 85% and ready to recover", it's down 85% and still burning cash with minimal revenue. The fundamentals haven't improved; the price just fell to match reality. **NBIS "Like ASTS at 25" Claim:** At $23B market cap, NBIS is actually priced similarly to ASTS ($23B). Both are already "discovered." The comparison doesn't hold. Your winner criteria works. Your forward picks need the same rigor you applied to the winners.
$HUMA. Do your own DD, but she is primed 🫡
HUMA OR SPCE that would be my pick
From that list, its a lot of space, AI, nuclear plays that paid off well. I'm disappointed HUMA tanked. Their blood vessel grafting biotech seems really promising. I've heard it's being successful in the Ukrainian war but don't have a ton of info on it.
$HUMA! Excerpt from page 129 of the NDAA Defense Bill that was just signed that describes Symvess (symvess.com) nearly word-for-word: https://preview.redd.it/akwf38w4088g1.png?width=905&format=png&auto=webp&s=23ce561ea3a89ede157ba12eefd11134bd4b93cd
HUMA has a lot of potential!
Looks like shorts are covering on HUMA
Does anybody wants to jump in HUMA with me?
HUMA just got 77.5 mil in financing without dilution.
HUMA, great product, questionnable management and longshot thinking on my part.
I meant to say "HUMA's" warrants cannot get executed at any time. Not until Apr 2026. And haven't all of their older warrants already expired?
$HUMA cancelled their $80M ATM and will likely issue a press release today about it. Rumors circulating that it might be bought out.
HUMA, Humacyte. Beaten down so low and so much potential.
Humacyte is on the verge of fundamentally and positively changing life as we know it. And if sustained buying pressure continues on the stock at these prices, not only will the 21% short interest start to back out (thereby pushing the price up) but both institutional and retail investors will start to buy in once they see the market recognizing the market opportunity for this company. Many institutional analysts already recognize the market opportunity, as reflected in their +130%, +500%, and +1800% price forecasts. I believe the stock has just started it's final and lowest reversal to the upside. Go take a look at the chart for yourself and read about what they are doing. $HUMA is the leader and first-mover in developing the next era of medical technology - universally implantable, regenerative human tissues and organ systems. Think of the future. Computer systems, space exploration, energy innovation - they have all already entered and are making their way through various phases of stock trading cycles. But not this space. This is not pharma and not your conventional med device or medtech - it is truly novel and at some point the price entry point on this stock will be a once in a generational opportunity. Well, I believe that entry point is right now or very soon. Given the fact that we are seeing risk off selling of the other tech sectors I mentioned earlier, it is no reach to theorize that the smart money is gearing up for accumulation in areas not yet tapped. $HUMA is likely one of them. Not only do they have all forecastable bad news behind them for the year, they now have enough cash on hand to take them through the next 12 months - a period in which we might only see good news releases, surprises, revenue and earnings beats to fund further operations and development. I am here to say that at right above $1, sustained buying pressure here could be just the kick needed to get in the rocket ship right before blast off. *not financial advice, you live and die by your own trading.
HUMA.. Great company that's primed for takeoff.. FDA approved, in use.. listed as overweight by most hedgefunds
$HUMA. And it's not just a squeeze candidate either, deep value. Will rocket launch upon nvidia/market recovery. Also a clear floor to use.
Pstv held...UNH,HUMA DEAL. What do yall think..
If you've been let down and don'tknow where to look, go take a look at $HUMA. Small cap Biotech is where you want to be right now into next year.
HUMA, DFLI, MBOT my plays for now.
$HUMA. DD is some random guy mentioned it yesterday and it got completely overlooked but I'm up 8% so far lmaooo.
What you guys think about HUMA?
I told you not to sleep on $DFLI two months ago. Don't sleep on $HUMA now. [divergence ](https://www.tradingview.com/chart/HUMA/iEVBKQeZ-Bullish-Divergences-on-Lower-Timeframes/)
Im liking $HUMA more and more at current price. Holding a few thousand shares and might add more next week.
HUMA no more fake meat, the future is fake esophagus.
VIVK a good play this week. Huge volume on monday with no real price movement = institutional accumulation. Was expecting something yesterday but it was a pretty flat day across the board. Holding strong for now. Trimming FEMY, CRMD, and HUMA today if these good ERs fetch me some profit and I’ll load up on more VIVK if price is still stable. Got a good feeling about this one.
$HUMA Q3 earnings tomorrow morning!
I'm there with you holding LPSN, KULR, FFAI, CRML, IBRX, HUMA, BYND, CLOV, OPEN, AIRE and OPEN
Lately, I’ve been getting in and out of many low-value stocks that have been pumped and dumped. If you get caught up in the dream of making 10x gains in these kinds of stocks, you’ll end up losing all your money. For me, these stocks have become more of a form of entertainment. On the first day, I invest 2k just to see what happens. If the stock goes up the next day, I add another 1k. If it keeps rising, I put in another 2k — but I never invest more than 5k in such stocks. I’ve taken this approach with stocks like BYND, DVLT, ASST, HUMA, FEMI, and DFLI. I’ve made 3–4x profits on some, lost money on others, but overall, it’s been fun.
HUMA is actually good with analysts but ratings. DFLI has a lot of people saying that under 1.35 is a good buy
idk, some analyst just raised the price target of HUMA from $2 to $20. I put a lol amount on Jan 16 $10 call and already down 68%.
Anyone looked into HUMA, started to see some buzz on it, haven’t done and DD tho…
I bought a few thousand shares and handful of Leaps for OPTT and HUMA recently. Check em out